Your browser doesn't support javascript.
loading
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis.
Solmi, Marco; Croatto, Giovanni; Fornaro, Michele; Schneider, Lynne Kolton; Rohani-Montez, S Christy; Fairley, Leanne; Smith, Nathalie; Bitter, István; Gorwood, Philip; Taipale, Heidi; Tiihonen, Jari; Cortese, Samuele; Dragioti, Elena; Rietz, Ebba Du; Nielsen, Rene Ernst; Firth, Joseph; Fusar-Poli, Paolo; Hartman, Catharina; Holt, Richard I G; Høye, Anne; Koyanagi, Ai; Larsson, Henrik; Lehto, Kelli; Lindgren, Peter; Manchia, Mirko; Nordentoft, Merete; Skonieczna-Zydecka, Karolina; Stubbs, Brendon; Vancampfort, Davy; Boyer, Laurent; De Prisco, Michele; Vieta, Eduard; Correll, Christoph U.
Afiliação
  • Solmi M; SCIENCES lab, Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada; Department of Mental Health, Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada; School of Epidemiology and Public Hea
  • Croatto G; Mental Health Department, AULSS 3 Serenissima, Mestre, Venice, Italy.
  • Fornaro M; Section of Psychiatry, Department of Neuroscience, Reproductive Science, and Dentistry, Federico II University of Naples, Naples, Italy.
  • Schneider LK; WebMD Global LLC, London, UK.
  • Rohani-Montez SC; WebMD Global LLC, London, UK.
  • Fairley L; WebMD Global LLC, London, UK.
  • Smith N; WebMD Global LLC, London, UK.
  • Bitter I; Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
  • Gorwood P; INSERM U1266, Institute of Psychiatry and Neurosciences of Paris (IPNP), Paris, France; GHU Paris Psychiatrie et Neurosciences (CMME, Sainte-Anne Hospital), Université de Paris, Paris, France.
  • Taipale H; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland; School of Pharmacy, University of Eastern
  • Tiihonen J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
  • Cortese S; Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; Solent NHS Trust, Southampton, UK; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampto
  • Dragioti E; Research Laboratory Psychology of Patients, Families, and Health Professionals, Department of Nursing, School of Health Sciences, University of Ioannina, Ioannina, Greece; Pain and Rehabilitation Centre, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
  • Rietz ED; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Nielsen RE; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark.
  • Firth J; Division of Psychology and Mental Health, The University of Manchester, Manchester, United Kingdom.
  • Fusar-Poli P; Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Italy; Outreach and Support in South-London (OASIS) service, South London and Maudlsey (SLaM) NHS Foundatio
  • Hartman C; University of Groningen, University Medical Center Groningen, Interdisciplinary Centre Psychopathology and Emotion regulation.
  • Holt RIG; Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Høye A; Department of Clinical Medicine, UiT The Arctic University of Norway and Division of Mental Health and Substance Abuse, University Hospital of North Norway, Tromsø, Norway.
  • Koyanagi A; Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.
  • Larsson H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Lehto K; Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
  • Lindgren P; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; The Swedish Institute for Health Economics, Lund, Sweden.
  • Manchia M; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy; Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Nordentoft M; Mental Health Centre Copenhagen, Department of Clinical Medicine, Copenhagen University Hospital, Denmark.
  • Skonieczna-Zydecka K; Department of Biochemical Science, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland. Electronic address: karzyd@pum.edu.pl.
  • Stubbs B; Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
  • Vancampfort D; Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium; University Psychiatric Centre KU Leuven, Kortenberg, Leuven, Belgium.
  • Boyer L; AP-HM, Aix-Marseille Univ., CEReSS-Health Service Research and Quality of Life Center, Marseille, France; FondaMental Foundation, Creteil, France.
  • De Prisco M; Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
  • Vieta E; Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
  • Correll CU; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Eur Neuropsychopharmacol ; 80: 55-69, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38368796
ABSTRACT
People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Global initiatives are needed to improve physical health in people with schizophrenia, local studies to identify actionable moderators.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia Limite: Humans País como assunto: Africa / Asia / Europa / Oceania Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia Limite: Humans País como assunto: Africa / Asia / Europa / Oceania Idioma: En Ano de publicação: 2024 Tipo de documento: Article